Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results


1.		A Long Term Safety Study With Atrasentan

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				M01-304 NCT00127478

Last Modified: 12/20/2007 First Published: 11/1/2001


2.		Phase III Randomized Study of Atrasentan in Patients With Non-Metastatic Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				19 and over				Pharmaceutical / Industry				ABBOTT-M00-244 ABBOTT-ABT-627, UCLA-0107068

Last Modified: 12/20/2007 First Published: 11/1/2001


3.		Phase III Randomized Study of Atrasentan in Patients With Metastatic Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				19 and over				Pharmaceutical / Industry				ABBOTT-M00-211 ABBOTT-627, UCLA-010506301

Last Modified: 4/14/2008 First Published: 10/1/2002


4.		Phase III Extension Study of Atrasentan in Patients With Hormone-Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				19 and over				Pharmaceutical / Industry				ABBOTT-M00-258 UCLA-0202002, NCI-G02-2110, NCT00046943

Last Modified: 7/6/2007 First Published: 6/1/2002


5.		Phase II Study of Atrasentan in Patients With Locally Recurrent or Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				ECOG-E6800 E6800, NCT00039429


6.		Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				19 and over				Pharmaceutical / Industry				M01-366 NCT00038662

First Published: 4/2/2008


7.		Phase II Study of Atrasentan Hydrochloride and Pegylated Liposomal Doxorubicin Hydrochloride as Second-Line Therapy in Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Adenocarcinoma, or Peritoneal Serous Papillary Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				VU-VICC-GYN-0288 VICC-GYN-0288, VU-VICC-020947, NCT00653328

Last Modified: 10/9/2006 First Published: 6/1/2001


8.		Phase I Study of Atrasentan in Patients With Progressive or Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NABTT-2008 JHOC-NABTT-2008, NABTT-2008, NCT00017264

Select All on One Page